Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alere Inc. stock logo
ALR
Alere
$1.32
$0.00
$34.41
$51.00
$43.05M0.8540,839 shsN/A
Electromed, Inc. stock logo
ELMD
Electromed
$20.53
-1.0%
$21.43
$13.74
$35.56
$172.17M0.473,896 shs75,889 shs
National HealthCare Co. stock logo
NHC
National HealthCare
$104.86
-1.1%
$100.41
$89.14
$138.49
$1.62B0.5558,686 shs271,511 shs
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
$17.76
-3.0%
$16.65
$2.03
$14.36
$166.91M1.1150,104 shs108,535 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alere Inc. stock logo
ALR
Alere
0.00%0.00%0.00%0.00%0.00%
Electromed, Inc. stock logo
ELMD
Electromed
0.00%+2.29%+0.88%-16.98%+45.09%
National HealthCare Co. stock logo
NHC
National HealthCare
0.00%+1.71%+3.22%+15.59%-0.93%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
-2.95%-10.12%-4.26%+24.98%-41.42%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alere Inc. stock logo
ALR
Alere
N/AN/AN/AN/AN/AN/AN/AN/A
Electromed, Inc. stock logo
ELMD
Electromed
1.1499 of 5 stars
2.05.00.00.00.61.70.0
National HealthCare Co. stock logo
NHC
National HealthCare
N/AN/AN/AN/AN/AN/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alere Inc. stock logo
ALR
Alere
0.00
N/AN/AN/A
Electromed, Inc. stock logo
ELMD
Electromed
4.00
Strong Buy$38.0085.09% Upside
National HealthCare Co. stock logo
NHC
National HealthCare
0.00
N/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ALR, NHC, ELMD, and NLTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Electromed, Inc. stock logo
ELMD
Electromed
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alere Inc. stock logo
ALR
Alere
$934.59M0.05N/AN/A$5.72 per share0.23
Electromed, Inc. stock logo
ELMD
Electromed
$61.44M2.80$0.50 per share41.36$5.10 per share4.03
National HealthCare Co. stock logo
NHC
National HealthCare
$1.37B1.18$6.69 per share15.68$59.41 per share1.77
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/A$11.08 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alere Inc. stock logo
ALR
Alere
-$29.92M-$1.20N/AN/AN/A-5.34%-20.78%-9.02%N/A
Electromed, Inc. stock logo
ELMD
Electromed
$5.15M$0.7927.37N/A11.34%15.71%13.37%N/A
National HealthCare Co. stock logo
NHC
National HealthCare
$66.80M$6.9213.14N/A10.03%6.87%4.68%N/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
-$57.56M-$3.11N/AN/AN/A-37.22%-30.91%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alere Inc. stock logo
ALR
Alere
N/AN/AN/AN/AN/A
Electromed, Inc. stock logo
ELMD
Electromed
N/AN/AN/AN/AN/A
National HealthCare Co. stock logo
NHC
National HealthCare
$2.562.44%N/A36.99%10 Years
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/A

Latest ALR, NHC, ELMD, and NLTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/8/2025
National HealthCare Co. stock logo
NHC
National HealthCare
quarterly$0.642.7%6/30/20256/30/20258/1/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alere Inc. stock logo
ALR
Alere
0.45
1.58
1.58
Electromed, Inc. stock logo
ELMD
Electromed
N/A
5.10
4.74
National HealthCare Co. stock logo
NHC
National HealthCare
0.14
1.80
1.77
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/A
15.33
15.33

Institutional Ownership

CompanyInstitutional Ownership
Alere Inc. stock logo
ALR
Alere
24.08%
Electromed, Inc. stock logo
ELMD
Electromed
40.82%
National HealthCare Co. stock logo
NHC
National HealthCare
56.44%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
52.37%

Insider Ownership

CompanyInsider Ownership
Alere Inc. stock logo
ALR
Alere
8.40%
Electromed, Inc. stock logo
ELMD
Electromed
14.00%
National HealthCare Co. stock logo
NHC
National HealthCare
14.97%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
1.58%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alere Inc. stock logo
ALR
Alere
10,40032.61 million29.87 millionOptionable
Electromed, Inc. stock logo
ELMD
Electromed
1608.39 million7.36 millionOptionable
National HealthCare Co. stock logo
NHC
National HealthCare
12,40015.46 million13.32 millionN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
909.40 million9.25 millionNo Data

Recent News About These Companies

(NGNE) Proactive Strategies
Neurogene concludes merger deal with Neoleukin Therapeutics
Pre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
Neoleukin Therapeutics Recent Insider Activity

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alere stock logo

Alere NYSE:ALR

Alere Inc. is a provider of health information through diagnostic tests. The Company's segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its joint venture with The Procter & Gamble Company (P&G). The Company's professional diagnostic solutions allow patients and their healthcare providers to work together to manage patients' conditions over the continuum of care, from the hospital to home. The Company offers lines of drugs-of-abuse tests, reagent systems and laboratory testing options.

Electromed stock logo

Electromed NYSE:ELMD

$20.53 -0.21 (-1.01%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$20.52 -0.02 (-0.07%)
As of 06/20/2025 05:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.

National HealthCare stock logo

National HealthCare NYSE:NHC

$104.86 -1.18 (-1.11%)
As of 06/20/2025 04:00 PM Eastern

National HealthCare Corporation engages in the operation of services to skilled nursing facilities, assisted and independent living facilities, homecare and hospice agencies, and health hospitals. Its skilled nursing facilities offer licensed therapy services, nutrition services, social services, activities, and housekeeping and laundry services, as well as medical services prescribed by physicians; and rehabilitative services, such as physical, speech, respiratory, and occupational therapy for patients recovering from strokes, heart attacks, orthopedic conditions, neurological illnesses, or other illnesses, injuries, or disabilities. The company's medical specialty units comprise memory care units and sub-cute nursing units that provide specialized care and programs for persons with Alzheimer's or related disorders; and assisted living facilities offer personal care services and assistance with general activities of daily living, such as dressing, bathing, meal preparation, and medication management. Its independent living facilities offers specially designed residential units for the active and ambulatory elderly and provide various ancillary services for residents, including restaurants, activity rooms and social areas; and behavioral health services to both adults and geriatric patients with psychiatric, emotional, and addictive disorders. In addition, the company's homecare agencies assist those who wish to stay at home or in assisted living residences but still require some degree of medical care or assistance with daily activities; hospice agencies that provides hospice and palliative care; and operates pharmacies, as well as managed care insurance solutions. Further, it offers management, accounting, and financial services; and leases its properties to third party operators. The company was founded in 1971 and is based in Murfreesboro, Tennessee.

Neoleukin Therapeutics stock logo

Neoleukin Therapeutics NASDAQ:NLTX

$17.76 -0.54 (-2.95%)
As of 06/20/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.